Cyclodextrin-related topics in the latest issue of JIPH
The following cyclodextrin-related papers in Journal of Inclusion Phenomena and Macrocyclic Chemistry. Volume 95 Number 3-4 might be interesting for the
Category: CD derivatives
Underdog Launches With $4M to Target “Toxic” Form of Cholesterol
Underdog Pharmaceuticals has launched with nearly $4 million in seed funding to develop treatments for atherosclerosis, a progressive condition in
Novel macrocycles – and old ones doing new tricks
A thematic issue of Beilstein Journal of Organic Chemistry entitled ‘Novel macrocycles – and old ones doing new tricks’ has
Cyclo Therapeutics Announces Completion of Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced
Advanced Materials Congress
The 33rd Assembly of Advanced Material Congress (AMC) will be held during 23-25 March 2020 in Stockholm, Sweden. The following
Cyclodextrin-based nanozymes
Nanozymes are nanomaterials with enzyme-like properties. These artificial enzymes have emerged more robust than the natural enzymes and find applications
Engineered cyclodextrin derivatives for spontaneous coating of highly porous metal-organic framework nanoparticles
Nanosized metal-organic frameworks (nanoMOFs) MIL-100(Fe) are highly porous and biodegradable materials that have emerged as promising drug nanocarriers. A challenging
Efficient Grafting of Cyclodextrin to Alginate and Performance of the Hydrogel for Release of Model Drug
Controlling the rate of release of molecules from a hydrogel is of high interest for various drug delivery systems and
Folate-Decorated Amphiphilic Cyclodextrins as Cell-Targeted Nanophototherapeutics
The group of Prof. Mazzaglia published on a ternary nanoassembly (SAP) composed of nonionic amphiphilic β-cyclodextrins (amphiphilic CD) incorporating pheophorbide
Clinical trial on Noninfectious Anterior Uveitis – SBECD offering disease resolution
Aldeyra Therapeutics Announced Results from the SOLACE Trial in Noninfectious Anterior Uveitis. The main points are: Statistical Significance Not Achieved